Ceria Therapeutics

Executive Summary

Ceria Therapeutics is a preclinical-stage biotechnology company focused on developing innovative RNA and gene therapies to address the downstream consequences of disease and restore the body's natural healing processes. Founded in 2021 and headquartered in Cambridge, MA, the company leverages proprietary synthetic RNA and solid inorganic nanoparticle manufacturing capabilities to create novel drug products. Ceria's integrated platform includes scalable production, advanced nanoparticle synthesis, aerosolized drug formulation, particle characterization, and preclinical testing, enabling a comprehensive approach to product development. By combining RNA therapeutics with targeted nanoparticle delivery, Ceria aims to overcome key limitations in current gene therapy modalities, such as off-target effects and immunogenicity, potentially unlocking new treatment avenues for a range of diseases. As a privately held company at the preclinical stage, Ceria has not yet disclosed specific therapeutic programs or timeline to the clinic. However, its robust manufacturing capabilities and platform technology position it as a potential partner for larger pharmaceutical companies seeking advanced RNA delivery solutions. The near-term outlook hinges on advancing lead candidates toward IND-enabling studies and securing strategic collaborations to validate its nanoparticle platform. With a strong foundation in synthetic RNA and nanoparticle engineering, Ceria represents an early-stage opportunity in the rapidly evolving field of nucleic acid therapeutics, though significant milestones are required to demonstrate clinical translation and de-risk the investment.

Upcoming Catalysts (preview)

• Q3 2026Lead Candidate Selection for IND-Enabling Studies60% success
• Q4 2026Partnership with Pharma for Nanoparticle Delivery Platform50% success
• Q2 2026Publication of Preclinical Data in Peer-Reviewed Journal70% success